Table 3

Risk of acute pancreatitis and duration of current use of antidiabetic drugs (nested case-control analysis)

Case subjectsControl subjectsOR (95% CI)*
n4195,000
Insulin
    Nonuse399 (95.2)4,650 (93.0)1 (referent)
    Short duration (<1 year)7 (1.7)82 (1.6)0.41 (0.17–1.00)
    Mid duration (1–3 years)5 (1.2)88 (1.8)0.34 (0.13–0.91)
    Long duration (>3 years)7 (1.7)158 (3.2)0.30 (0.13–0.68)
Metformin
    Nonuse328 (78.3)4,261 (85.2)1 (referent)
    Short duration (<1 year)26 (6.2)213 (4.3)0.88 (0.53–1.47)
    Mid duration (1–3 years)31 (7.4)237 (4.7)0.93 (0.58–1.49)
    Long duration (>3 years)18 (4.3)205 (4.1)0.50 (0.28–0.91)
Sulfonylureas
    Nonuse334 (79.7)4,460 (89.2)1 (referent)
    Short duration (<1 year)13 (3.1)125 (2.5)0.81 (0.42–1.57)
    Mid duration (1–3 years)25 (6.0)156 (3.1)1.20 (0.70–2.03)
    Long duration (>3 years)31 (7.4)193 (3.9)1.66 (1.01–2.74)
Thiazolidinediones
    Nonuse396 (94.5)4,864 (97.3)1 (referent)
    Short duration (<1 year)11 (2.6)57 (1.1)1.28 (0.61–2.68)
    Mid duration (1–3 years)7 (1.7)46 (0.9)1.19 (0.49–2.90)
    Long duration (>3 years)2 (0.5)14 (0.3)1.27 (0.23–6.89)
Other antidiabetic drugs
    Nonuse412 (98.3)4,962 (99.2)1 (referent)
    Short duration (<1 year)1 (0.2)9 (0.2)1.24 (0.13–11.82)
    Mid duration (1–3 years)1 (0.2)8 (0.2)0.94 (0.11–8.14)
    Long duration (>3 years)2 (0.5)10 (0.2)1.85 (0.34–10.10)
  • Data are n (%) unless otherwise indicated.

  • *Adjusted for all variables included in the table plus those in the fully adjusted model of Table 2.

  • †Baseline category.